Red X iconGreen tick iconYellow tick icon

Contact Details

Email
abigail.bland@otago.ac.nz
Position
Postdoctoral Fellow
Department
Department of Pharmacology and Toxicology
Research summary
Cancer drug targets and chemotherapy-induced cardiotoxicity

Publications

Berry, M., Bland, A., & Ashton, J. (2023). Differing cell cycle responses for alectinib and SHP099 in variant 1 and variant 3 ALK+ non-small cell lung cancer cell lines. Journal of Thoracic Oncology, 18(Suppl. 11), S424-S425. doi: 10.1016/j.jtho.2023.09.766

Berry, M. A., Bland, A. R., & Ashton, J. C. (2023). Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors. Scientific Reports, 13, 10041. doi: 10.1038/s41598-023-37006-2

Ashton, J. C., Bland, A. R., & Sammut, I. A. (2023). Treatment of lorlatinib induced hypercholesterolemia with PCSK9 inhibitors: A new solution to an emerging need in non-small cell lung cancer therapy. Open Journal of Clinical & Medical Case Reports, 9(11). [Case Study].

Bland, A. R., Ashton, J. C., Kamal, M. A., & Sahebkar, A. (2023). The current evidence for the therapeutic role of curcumin in Alzheimer's disease. CNS & Neurological Disorders: Drug Targets, 22(3), 318-320. doi: 10.2174/1871527321666220119105836

Watts, B., Berry, M., Bland, A., Badart, M., Hawkins, B., & Ashton, J. (2022). Tumour cell suppression by spiroleucettadine through dual regulation of cell cycle and apoptosis. F1000Research, 11, 1328. doi: 10.12688/f1000research.126754.1

Berry, M. A., Bland, A. R., & Ashton, J. C. (2023). Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors. Scientific Reports, 13, 10041. doi: 10.1038/s41598-023-37006-2

Journal - Research Article

Berry, M., Bland, A., & Ashton, J. (2023). Differing cell cycle responses for alectinib and SHP099 in variant 1 and variant 3 ALK+ non-small cell lung cancer cell lines. Journal of Thoracic Oncology, 18(Suppl. 11), S424-S425. doi: 10.1016/j.jtho.2023.09.766

Journal - Research Article

Bland, A. R., Payne, F. M., Ashton, J. C., Jamialahmadi, T., & Sahebkar, A. (2022). The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacological Research, 175, 105986. doi: 10.1016/j.phrs.2021.105986

Journal - Research Article

Bland, A. R., Shrestha, N., Berry, M., Wilson, C., & Ashton, J. C. (2022). Experimental determination of cancer drug targets with independent mechanisms of resistance. Current Cancer Drug Targets, 22(2), 97-107. doi: 10.2174/1568009622666220107152014

Journal - Research Article

Johnston, H. M., Kueh, J. T. B., Hartley, R. H., Bland, A. R., Payne, F. M., Harrison, J. C., Sammut, I. A., & Larsen, D. S. (2022). Utilising fluorescent reporters to probe the mode of action of norbornen-7-one CO releasing molecules. Organic & Biomolecular Chemistry, 20, 5812-5819. doi: 10.1039/d2ob01076c

Journal - Research Article

Watts, B., Berry, M., Bland, A., Badart, M., Hawkins, B., & Ashton, J. (2022). Tumour cell suppression by spiroleucettadine through dual regulation of cell cycle and apoptosis. F1000Research, 11, 1328. doi: 10.12688/f1000research.126754.1

Journal - Research Article

Badart, M. P., Barnes, E. M., Cording, A. P., Gilmer, S. C. L., Billinghurst, I. D., Edupuganti, V. V. S. R., … Bland, A. R., Bower, R. L., Rana, Z., Ferguson, S. A., Opel Reading, H. K., Cook, G. M., Rosengren, R. J., Krause, K. L., Gamble, A. B., Ashton, J. C., & Hawkins, B. C. (2021). Synthesis and biological evaluation of (-) and (+)-spiroleucettadine and analogues. ChemMedChem, 16, 1308-1315. doi: 10.1002/cmdc.202000954

Journal - Research Article

Bland, A. R., & Ashton, J. C. (2021). Considerations for whole-slide analysis of murine xenografts experiments. Journal of Histochemistry & Cytochemistry, 69(10), 627-631. doi: 10.1369/00221554211046994

Journal - Research Article

Bland, A. R., Shrestha, N., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2021). The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models. Biochemical Pharmacology, 183, 114345. doi: 10.1016/j.bcp.2020.114345

Journal - Research Article

Shrestha, N., Bland, A. R., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2020). Inhibition of mitogen-activated protein kinase kinase alone and in combination with anaplastic lymphoma kinase (ALK) inhibition suppresses tumor growth in a mouse model of ALK-positive lung cancer. Journal of Pharmacology & Experimental Therapeutics, 374, 134-140. doi: 10.1124/jpet.120.266049

Journal - Research Article

Bland, A. R., Bower, R. L., Nimick, M., Hawkins, B. C., Rosengren, R. J., & Ashton, J. C. (2019). Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. European Journal of Pharmacology, 865, 172749. doi: 10.1016/j.ejphar.2019.172749

Journal - Research Article

Shrestha, N., Lateef, Z., Martey, O., Bland, A. R., Nimick, M., Rosengren, R., & Ashton, J. C. (2019). Does the mouse tail vein injection method provide a good model of lung cancer? F1000Research, 8, 190. doi: 10.12688/f1000research.17964.1

Journal - Research Article

Ashton, J. C., Bland, A. R., & Sammut, I. A. (2023). Treatment of lorlatinib induced hypercholesterolemia with PCSK9 inhibitors: A new solution to an emerging need in non-small cell lung cancer therapy. Open Journal of Clinical & Medical Case Reports, 9(11). [Case Study].

Journal - Research Other

Bland, A. R., Ashton, J. C., Kamal, M. A., & Sahebkar, A. (2023). The current evidence for the therapeutic role of curcumin in Alzheimer's disease. CNS & Neurological Disorders: Drug Targets, 22(3), 318-320. doi: 10.2174/1871527321666220119105836

Journal - Research Other

Bland, A. R., Ashton, J. C., Kamal, M. A., & Sahebkar, A. (2022). The current state of evidence for the therapeutic role of curcumin in Alzheimer's disease. CNS & Neurological Disorders: Drug Targets, 21. doi: 10.2174/1871527321666220119105836

Journal - Research Other

Keshavarz Shahbaz, S., Koushki, K., Ayati, S. H., Bland, A. R., Bezsonov, E. E., & Sahebkar, A. (2021). Inflammasomes and colorectal cancer. Cells, 10, 2172. doi: 10.3390/cells10092172

Journal - Research Other

Radbakhsh, S., Barreto, G. E., Bland, A. R., & Sahebkar, A. (2021). Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes. BioFactors, 47, 570-586. doi: 10.1002/biof.1735

Journal - Research Other

Bland, A. R., Shrestha, N., Rosengren, R. J., & Ashton, J. C. (2020). Does crizotinib auto-inhibit CYP3A in vivo? [Brief report]. Pharmacology, 105, 715-718. doi: 10.1159/000506996

Journal - Research Other

Hassanzadeh, S., Read, M. I., Bland, A. R., Majeed, M., Jamialahmadi, T., & Sahebkar, A. (2020). Curcumin: An inflammasome silencer. Pharmacological Research, 159, 104921. doi: 10.1016/j.phrs.2020.104921

Journal - Research Other

Back to top